Commentary & Perspectives

Meeting the GLP-1 Challenge with High-Resolution Mass Spec

Veloxity Labs and SCIEX team up to advance peptide bioanalysis; here, the teams discuss how the GLP-1 boom is reshaping workflows and raising the bar for analytical performance

Share

Peptide therapeutics are expanding rapidly, particularly GLP-1 receptor agonists, prompting bioanalytical labs to improve their methodologies. Veloxity Labs has integrated the SCIEX ZenoTOF 8600 system to enhance sensitivity, selectivity, and speed in peptide analysis. As noted by President Shane Needham, the combination of high-resolution mass spectrometry and traditional methods allows for better handling of complex matrices, smaller sample volumes, and efficient workflows. Collaborations like the one between Veloxity and SCIEX aim to meet the evolving challenges in peptide bioanalysis, ensuring timely delivery of innovative therapeutics.

Original Source(s)

Meeting the GLP-1 Challenge with High-Resolution Mass Spec

Veloxity Labs and SCIEX team up to advance peptide bioanalysis; here, the teams discuss how the GLP-1 boom is reshaping workflows and raising the bar for analytical performance

  • by James Strachan

  • February 25, 2026

  • 7 min

Related Content

AI Tools Expand in Thyroid Cancer Diagnosis

Uptake will require “compelling evidence that these systems can reduce time and effort while at least maintaining, if not improving, diagnostic accuracy, making the cost of implementation and continued usage worthwhile.”

Human-Relevant Discovery: iPSC Models and the Future of Rare Disease R&D

A Q&A with iXCells Biotechnologies CEO, Steve Smith

  • February 25, 2026

  • 9 min
PFAS Bioaccumulation: The Biology of Forever

Carrie McDonough explores how PFAS move, bind, and transform within us – redefining what exposure really means

  • February 23, 2026

  • 20 min